Skip to main content
Figure 3 | Annals of General Psychiatry

Figure 3

From: Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study

Figure 3

Median values for sleep latency at baseline and at Weeks 1 through 4. Median sleep latency (baseline; Week 1 through 4) were obtained in elderly patients receiving eszopiclone 1 mg (A) or 2 mg (B) and in nonelderly patients receiving eszopiclone 2 mg (C) or 3 mg (D). *P < 0.001 versus baseline for all treatment groups at all time points.

Back to article page

Annals of General Psychiatry

ISSN: 1744-859X